By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Gram-Positive Bacteria have been published. According to news originating from Houston, Texas, by NewsRx correspondents, research stated, "The Verigene Clostridium difficile Nucleic Acid test (Verigene CDF test) (Nanosphere, Northbrook, IL) is a multiplex qualitative PCR assay that utilizes a nanoparticle-based array hybridization method to detect C. difficile tcdA and tcdB in fecal specimens. In addition, the assay detects binary toxin gene sequences and the single base pair deletion at nucleotide 117 (Delta 117) in tcdC to provide a presumptive identification of the epidemic strain 027/NAP1/BI (referred to here as ribotype 027)."
Our news journalists obtained a quote from the research, "This study compared the Verigene CDF test with anaerobic direct and enriched toxigenic culture on stool specimens from symptomatic patients among five geographically diverse laboratories within the United States. The Verigene CDF test was performed according to the manufacturer's instructions, and the reference methods performed by a central laboratory included direct culture onto cycloserine cefoxitin fructose agar (CCFA) and enriched culture using cycloserine cefoxitin mannitol broth with taurocholate and lysozyme. Recovered isolates were identified as C. difficile using gas liquid chromatography and were tested for toxin using a cell culture cytotoxicity neutralization assay. Strains belonging to ribotype 027 were determined by PCR ribotyping and bidirectional sequencing for Delta 117 in tcdC. A total of 1,875 specimens were evaluable. Of these, 275 specimens (14.7%) were culture positive by either direct or enriched culture methods. Compared to direct culture alone, the overall sensitivity, specificity, positive predictive value, and negative predictive value for the Verigene CDF test were 98.7%, 87.5%, 42%, and 99.9%, respectively. Compared to combined direct and enriched culture results, the sensitivity, specificity, positive predictive value, and negative predictive values of the Verigene CDF test were 90.9%, 92.5%, 67.6%, and 98.3%, respectively. Of the 250 concordantly culture-positive specimens, 59 (23.6%) were flagged as 'hypervirulent'; 53 were confirmed as ribotype 027, and all 59 possessed Delta 117 in tcdC. Time to results was approximately 2.5 h per specimen."
According to the news editors, the research concluded: "The Verigene CDF test is a novel nucleic acid microarray that reliably detects both C. difficile toxins A and B in unformed stool specimens and appears to adequately identify ribotype 027 isolates."
For more information on this research see: Multicenter Evaluation of the Verigene Clostridium difficile Nucleic Acid Assay. Journal of Clinical Microbiology, 2013;51(12):4120-4125. Journal of Clinical Microbiology can be contacted at: Amer Soc Microbiology, 1752 N St NW, Washington, DC 20036-2904, USA (see also Gram-Positive Bacteria).
The news correspondents report that additional information may be obtained from K.C. Carroll, Microbiol Specialists, Houston, TX, United States. Additional authors for this research include B.W. Buchan, S. Tan, P.D. Stamper, K.M. Riebe, P. Pancholi, C. Kelly, A. Rao, R. Fader, R. Cavagnolo, W. Watson, R.V. Goering, E.A. Trevino, A.S. Weissfeld and N.A. Ledeboer.
Keywords for this news article include: Texas, Houston, United States, Clostridium difficile, Gram-Positive Bacteria, North and Central America, Gram-Positive Endospore-Forming Rods, Gram-Positive Endospore-Forming Bacteria
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC